Tyler Van Buren
Stock Analyst at TD Cowen
(2.47)
# 2,285
Out of 5,154 analysts
62
Total ratings
46%
Success rate
1.94%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SLNO Soleno Therapeutics | Maintains: Buy | $120 → $85 | $39.68 | +114.21% | 1 | Feb 26, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $24.00 | +45.83% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $56.50 | -20.35% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $3.04 | - | 1 | Dec 2, 2025 | |
| BHVN Biohaven | Maintains: Buy | $50 → $15 | $9.92 | +51.21% | 3 | Nov 5, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $30.55 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $27.24 | +46.84% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $65.36 | +45.35% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $143.93 | -13.15% | 6 | Oct 23, 2025 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | n/a | $33.19 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $61.88 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.30 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $18.47 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $32.97 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $52.52 | +14.24% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $5.74 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $6.85 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,030 → $1,200 | $759.86 | +57.92% | 7 | Jul 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $35.87 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $29.86 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $40.15 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $114.33 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $73.05 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.33 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $32.97 | +112.31% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.30 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $13.60 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $35.04 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $12.07 | +1,764.13% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $6.98 | +12,435.82% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $15.10 | +164.90% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $13.57 | +121.08% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.33 | +3,659.40% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.50 | +5,891.61% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $11.54 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $31.05 | - | 1 | Aug 4, 2017 |
Soleno Therapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $120 → $85
Current: $39.68
Upside: +114.21%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $24.00
Upside: +45.83%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $56.50
Upside: -20.35%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $3.04
Upside: -
Biohaven
Nov 5, 2025
Maintains: Buy
Price Target: $50 → $15
Current: $9.92
Upside: +51.21%
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $30.55
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $27.24
Upside: +46.84%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $65.36
Upside: +45.35%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $143.93
Upside: -13.15%
IDEAYA Biosciences
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $33.19
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $61.88
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.30
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $18.47
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $32.97
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $52.52
Upside: +14.24%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $5.74
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $6.85
Upside: -
Jul 23, 2024
Maintains: Buy
Price Target: $1,030 → $1,200
Current: $759.86
Upside: +57.92%
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $35.87
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $29.86
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $40.15
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $114.33
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $73.05
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $32.97
Upside: +112.31%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $2.30
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $13.60
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $35.04
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $12.07
Upside: +1,764.13%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $6.98
Upside: +12,435.82%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $15.10
Upside: +164.90%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $13.57
Upside: +121.08%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.33
Upside: +3,659.40%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.50
Upside: +5,891.61%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $11.54
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $31.05
Upside: -